The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Biomarker Market Research Report 2024
Synopsis
Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids.
The global Cancer Biomarker market was valued at US$ 19580 million in 2023 and is anticipated to reach US$ 42170 million by 2030, witnessing a CAGR of 11.4% during the forecast period 2024-2030.
North American market for Cancer Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Cancer Biomarker include Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Biomérieux SA and Merck & Co., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biomarker.
Report Scope
The Cancer Biomarker market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Biomarker manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
Bio-Rad Laboratories
Roche Diagnostics
Qiagen
Illumina
GE Healthcare
Agilent Technologies
Biomérieux SA
Merck & Co.
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation
Myriad Genetics
Sysmex Corporation
Hologic
Quest Diagnostics
Segment by Type
Protein Biomarker
Genetic Biomarker
Segment by Application
Diagnostics
Research
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Biomarker manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Biomarker in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids.
The global Cancer Biomarker market was valued at US$ 19580 million in 2023 and is anticipated to reach US$ 42170 million by 2030, witnessing a CAGR of 11.4% during the forecast period 2024-2030.
North American market for Cancer Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Cancer Biomarker include Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Biomérieux SA and Merck & Co., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biomarker.
Report Scope
The Cancer Biomarker market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Biomarker manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
Bio-Rad Laboratories
Roche Diagnostics
Qiagen
Illumina
GE Healthcare
Agilent Technologies
Biomérieux SA
Merck & Co.
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation
Myriad Genetics
Sysmex Corporation
Hologic
Quest Diagnostics
Segment by Type
Protein Biomarker
Genetic Biomarker
Segment by Application
Diagnostics
Research
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Biomarker manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Biomarker in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Cancer Biomarker Market Overview
1.1 Product Overview and Scope of Cancer Biomarker
1.2 Cancer Biomarker Segment by Type
1.2.1 Global Cancer Biomarker Market Value Comparison by Type (2024-2030)
1.2.2 Protein Biomarker
1.2.3 Genetic Biomarker
1.3 Cancer Biomarker Segment by Application
1.3.1 Global Cancer Biomarker Market Value by Application: (2024-2030)
1.3.2 Diagnostics
1.3.3 Research
1.3.4 Others
1.4 Global Cancer Biomarker Market Size Estimates and Forecasts
1.4.1 Global Cancer Biomarker Revenue 2019-2030
1.4.2 Global Cancer Biomarker Sales 2019-2030
1.4.3 Global Cancer Biomarker Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cancer Biomarker Market Competition by Manufacturers
2.1 Global Cancer Biomarker Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cancer Biomarker Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cancer Biomarker Average Price by Manufacturers (2019-2024)
2.4 Global Cancer Biomarker Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Biomarker, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Biomarker, Product Type & Application
2.7 Cancer Biomarker Market Competitive Situation and Trends
2.7.1 Cancer Biomarker Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Biomarker Players Market Share by Revenue
2.7.3 Global Cancer Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Biomarker Retrospective Market Scenario by Region
3.1 Global Cancer Biomarker Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cancer Biomarker Global Cancer Biomarker Sales by Region: 2019-2030
3.2.1 Global Cancer Biomarker Sales by Region: 2019-2024
3.2.2 Global Cancer Biomarker Sales by Region: 2025-2030
3.3 Global Cancer Biomarker Global Cancer Biomarker Revenue by Region: 2019-2030
3.3.1 Global Cancer Biomarker Revenue by Region: 2019-2024
3.3.2 Global Cancer Biomarker Revenue by Region: 2025-2030
3.4 North America Cancer Biomarker Market Facts & Figures by Country
3.4.1 North America Cancer Biomarker Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cancer Biomarker Sales by Country (2019-2030)
3.4.3 North America Cancer Biomarker Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Biomarker Market Facts & Figures by Country
3.5.1 Europe Cancer Biomarker Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cancer Biomarker Sales by Country (2019-2030)
3.5.3 Europe Cancer Biomarker Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Biomarker Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Biomarker Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cancer Biomarker Sales by Country (2019-2030)
3.6.3 Asia Pacific Cancer Biomarker Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Biomarker Market Facts & Figures by Country
3.7.1 Latin America Cancer Biomarker Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cancer Biomarker Sales by Country (2019-2030)
3.7.3 Latin America Cancer Biomarker Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Biomarker Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Biomarker Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cancer Biomarker Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cancer Biomarker Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Biomarker Sales by Type (2019-2030)
4.1.1 Global Cancer Biomarker Sales by Type (2019-2024)
4.1.2 Global Cancer Biomarker Sales by Type (2025-2030)
4.1.3 Global Cancer Biomarker Sales Market Share by Type (2019-2030)
4.2 Global Cancer Biomarker Revenue by Type (2019-2030)
4.2.1 Global Cancer Biomarker Revenue by Type (2019-2024)
4.2.2 Global Cancer Biomarker Revenue by Type (2025-2030)
4.2.3 Global Cancer Biomarker Revenue Market Share by Type (2019-2030)
4.3 Global Cancer Biomarker Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cancer Biomarker Sales by Application (2019-2030)
5.1.1 Global Cancer Biomarker Sales by Application (2019-2024)
5.1.2 Global Cancer Biomarker Sales by Application (2025-2030)
5.1.3 Global Cancer Biomarker Sales Market Share by Application (2019-2030)
5.2 Global Cancer Biomarker Revenue by Application (2019-2030)
5.2.1 Global Cancer Biomarker Revenue by Application (2019-2024)
5.2.2 Global Cancer Biomarker Revenue by Application (2025-2030)
5.2.3 Global Cancer Biomarker Revenue Market Share by Application (2019-2030)
5.3 Global Cancer Biomarker Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific
6.1.1 Thermo Fisher Scientific Corporation Information
6.1.2 Thermo Fisher Scientific Description and Business Overview
6.1.3 Thermo Fisher Scientific Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Thermo Fisher Scientific Cancer Biomarker Product Portfolio
6.1.5 Thermo Fisher Scientific Recent Developments/Updates
6.2 Bio-Rad Laboratories
6.2.1 Bio-Rad Laboratories Corporation Information
6.2.2 Bio-Rad Laboratories Description and Business Overview
6.2.3 Bio-Rad Laboratories Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bio-Rad Laboratories Cancer Biomarker Product Portfolio
6.2.5 Bio-Rad Laboratories Recent Developments/Updates
6.3 Roche Diagnostics
6.3.1 Roche Diagnostics Corporation Information
6.3.2 Roche Diagnostics Description and Business Overview
6.3.3 Roche Diagnostics Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Diagnostics Cancer Biomarker Product Portfolio
6.3.5 Roche Diagnostics Recent Developments/Updates
6.4 Qiagen
6.4.1 Qiagen Corporation Information
6.4.2 Qiagen Description and Business Overview
6.4.3 Qiagen Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Qiagen Cancer Biomarker Product Portfolio
6.4.5 Qiagen Recent Developments/Updates
6.5 Illumina
6.5.1 Illumina Corporation Information
6.5.2 Illumina Description and Business Overview
6.5.3 Illumina Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Illumina Cancer Biomarker Product Portfolio
6.5.5 Illumina Recent Developments/Updates
6.6 GE Healthcare
6.6.1 GE Healthcare Corporation Information
6.6.2 GE Healthcare Description and Business Overview
6.6.3 GE Healthcare Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GE Healthcare Cancer Biomarker Product Portfolio
6.6.5 GE Healthcare Recent Developments/Updates
6.7 Agilent Technologies
6.6.1 Agilent Technologies Corporation Information
6.6.2 Agilent Technologies Description and Business Overview
6.6.3 Agilent Technologies Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Agilent Technologies Cancer Biomarker Product Portfolio
6.7.5 Agilent Technologies Recent Developments/Updates
6.8 Biomérieux SA
6.8.1 Biomérieux SA Corporation Information
6.8.2 Biomérieux SA Description and Business Overview
6.8.3 Biomérieux SA Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biomérieux SA Cancer Biomarker Product Portfolio
6.8.5 Biomérieux SA Recent Developments/Updates
6.9 Merck & Co.
6.9.1 Merck & Co. Corporation Information
6.9.2 Merck & Co. Description and Business Overview
6.9.3 Merck & Co. Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Merck & Co. Cancer Biomarker Product Portfolio
6.9.5 Merck & Co. Recent Developments/Updates
6.10 Abbott Laboratories
6.10.1 Abbott Laboratories Corporation Information
6.10.2 Abbott Laboratories Description and Business Overview
6.10.3 Abbott Laboratories Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Abbott Laboratories Cancer Biomarker Product Portfolio
6.10.5 Abbott Laboratories Recent Developments/Updates
6.11 Becton, Dickinson and Company
6.11.1 Becton, Dickinson and Company Corporation Information
6.11.2 Becton, Dickinson and Company Cancer Biomarker Description and Business Overview
6.11.3 Becton, Dickinson and Company Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Becton, Dickinson and Company Cancer Biomarker Product Portfolio
6.11.5 Becton, Dickinson and Company Recent Developments/Updates
6.12 Danaher Corporation
6.12.1 Danaher Corporation Corporation Information
6.12.2 Danaher Corporation Cancer Biomarker Description and Business Overview
6.12.3 Danaher Corporation Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Danaher Corporation Cancer Biomarker Product Portfolio
6.12.5 Danaher Corporation Recent Developments/Updates
6.13 Myriad Genetics
6.13.1 Myriad Genetics Corporation Information
6.13.2 Myriad Genetics Cancer Biomarker Description and Business Overview
6.13.3 Myriad Genetics Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Myriad Genetics Cancer Biomarker Product Portfolio
6.13.5 Myriad Genetics Recent Developments/Updates
6.14 Sysmex Corporation
6.14.1 Sysmex Corporation Corporation Information
6.14.2 Sysmex Corporation Cancer Biomarker Description and Business Overview
6.14.3 Sysmex Corporation Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sysmex Corporation Cancer Biomarker Product Portfolio
6.14.5 Sysmex Corporation Recent Developments/Updates
6.15 Hologic
6.15.1 Hologic Corporation Information
6.15.2 Hologic Cancer Biomarker Description and Business Overview
6.15.3 Hologic Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Hologic Cancer Biomarker Product Portfolio
6.15.5 Hologic Recent Developments/Updates
6.16 Quest Diagnostics
6.16.1 Quest Diagnostics Corporation Information
6.16.2 Quest Diagnostics Cancer Biomarker Description and Business Overview
6.16.3 Quest Diagnostics Cancer Biomarker Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Quest Diagnostics Cancer Biomarker Product Portfolio
6.16.5 Quest Diagnostics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Biomarker Industry Chain Analysis
7.2 Cancer Biomarker Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Biomarker Production Mode & Process
7.4 Cancer Biomarker Sales and Marketing
7.4.1 Cancer Biomarker Sales Channels
7.4.2 Cancer Biomarker Distributors
7.5 Cancer Biomarker Customers
8 Cancer Biomarker Market Dynamics
8.1 Cancer Biomarker Industry Trends
8.2 Cancer Biomarker Market Drivers
8.3 Cancer Biomarker Market Challenges
8.4 Cancer Biomarker Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
